AI Science Tracker

Evo

5 discoveries name this family, 2024 to 2026

Where Evo appears in the catalog

Why linked?

These associations match family names in discovery titles and technology text. They are not verified model-version assignments or causal attribution. Missing links do not establish absence of use. A record may link to multiple families.

Represented fields

biology · 5 linked records

Test contexts

direct test · 4 linked records
retrospective or benchmark · 1 linked records

Annotation coverage

Evidence annotation present · 5 linked records

Examples

Up to three linked records, newest publication date first, then stable ID. This selection is not a ranking.

Discoveries

Evo 2 uses in-context learning to design de novo regulatory sequences with only tens of examples

Arc Institute reports that Evo 2 designs functional regulatory sequences from 4 to 64 in-context examples without extra training, with 30-50% yield. Of nine AI-designed enhancers delivered by AAV to mice, seven drove detectable expression and two labeled layer 5 extratelencephalic neurons with 73% and 95% specificity. Results are bioRxiv preprints; in vivo work covers only layer 5 enhancers, and other designs (proteins, CRISPR loci, antibodies, phage genomes) are computational only.

Technology: Evo 2 (genomic language model); in-context learning; reinforcement learning post-training

Family Evo: profile · models page

Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Preprint
  • Test type: direct test
  • Tested: Nine AI-designed enhancers were delivered by AAV to mice: seven drove detectable expression and two labeled layer 5 extratelencephalic neurons with 73% and 95% specificity.
  • Still unknown: Only layer 5 enhancers were tested in vivo; the authors plan other cell types, and designs beyond enhancers (proteins, CRISPR loci, antibodies, phage genomes) are computational only.
  • AI role: Evo 2 generated regulatory sequences from 4 to 64 in-context examples; reinforcement learning with predictive reward models sharpened cell-type specificity.

Evidence sources: https://arcinstitute.org/news/evo-2-in-context-learning

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: not linked in this catalog; this does not mean no paper exists.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Evo genomic language model designs functional toxin-antitoxin and anti-CRISPR systems

Evo used genomic context to generate functional bacterial defence-system components. The paper reports an AI-generated toxin and low-sequence-similarity antitoxins that neutralized it in growth assays, including antitoxins that also acted against multiple natural toxins; it also reports five generated anti-CRISPR proteins that protected bacteria against Cas9 activity in cell and phage assays. Two generated anti-CRISPR proteins lacked significant sequence similarity to known proteins. These experiments demonstrate function-guided genomic design beyond simple copying of natural sequences.

Technology: Evo 1.5, a long-context generative genomic language model trained on prokaryotic DNA sequences

Family Evo: profile · models page

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: The paper reports an AI-generated toxin and low-sequence-similarity antitoxins that neutralized it in growth assays, including antitoxins that also acted against multiple natural toxins; it also reports five generated anti-CRISPR proteins that protected bacteria against Cas9 activity in cell and phage assays.
  • Still unknown: This is a set of functional in-vitro bacterial assays, not evidence of therapeutic use, broad host range or ecological performance. One generated toxin had 71% sequence identity to a known RelE toxin; novelty is especially supported by low-similarity antitoxins and anti-CRISPRs, two of which lacked significant sequence identity to known proteins. Earlier Evo phage-genome design and Evo 2 regulatory-sequence work are different papers and different functional results; this row is limited to the toxin-antitoxin/anti-CRISPR findings in the cited Nature article.
  • AI role: Researchers prompted Evo 1.5 with genomic contexts that associate functionally related bacterial genes and used it to generate candidate toxin-antitoxin and anti-CRISPR sequences. Candidates were filtered computationally, synthesized/expressed and tested in bacterial growth, Cas9-protection and phage assays. AI generated candidates; the biological activity was established experimentally.

Evidence sources: https://www.nature.com/articles/s41586-025-09749-7.pdf

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Arc Institute

First bacteriophage genomes designed by a genome language model

The Arc Institute group used Evo to design genomes resembling that of phage ΦX174: of 285 designs, 16 yielded functional phages (67–392 mutations from the closest natural one; 13 had never-seen mutations). They infect only two E. coli strains; a cocktail overcame resistance in three evolved strains. bioRxiv preprint; peer review is unconfirmed.

Technology: Evo (genome language model)

Family Evo: profile · models page

Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Preprint
  • Test type: direct test
  • Tested: Of 285 Evo-designed genomes, 16 were synthesized and gave functional phages in E. coli, and these were tested for fitness, host range and, for three resistant strains, a phage cocktail.
  • Still unknown: The source states host range was limited to E. coli C and W, all 16 phages were based on the phiX174 template, and clinical use is not shown.
  • AI role: Evo, fine-tuned on Microviridae sequences, generated whole phage genomes resembling phiX174.

Evidence sources: https://arcinstitute.org/news/hie-king-first-synthetic-phage · https://www.biorxiv.org/content/10.1101/2025.09.12.675911

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 5/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Arc Institute

Evo 2: the largest AI model for biology

Trained on more than 9.3 trillion nucleotides from over 128,000 genomes, it reads sequences up to 1 million nucleotides, flags harmful mutations, and designs genetic elements and genomes as long as those of simple bacteria. In BRCA1 tests it exceeds 90% accuracy in distinguishing benign from potentially pathogenic variants (a result limited to that gene). Preprint; human pathogens were excluded from training.

Technology: Evo 2 (genome language model)

Family Evo: profile · models page

Publication: Preprint · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Preprint
  • Test type: retrospective or benchmark
  • Tested: The model was tested on BRCA1 variants, where it reached over 90% accuracy distinguishing benign from potentially pathogenic mutations, and on identifying genetic changes affecting protein function and fitness.
  • Still unknown: The source reports the BRCA1 result for one gene only and states no other limitations beyond human pathogens being excluded from training.
  • AI role: A genome language model trained on 9.3 trillion nucleotides flags harmful mutations and designs genetic elements.

Evidence sources: https://arcinstitute.org/news/evo2

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Evo: a foundation model for DNA, from molecules to genomes

Published in Science, Evo (Arc Institute, Stanford, and UC Berkeley) designed EvoCas9-1, a CRISPR system sharing only about 73% of its sequence with CRISPR-Cas9 but with comparable activity after eleven designs, and new IS200/IS605 transposons that cut and paste DNA. The team calls this the beginning and conducted an ethics and safety study.

Technology: Evo (DNA foundation model)

Family Evo: profile · models page

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Evo was prompted to generate CRISPR systems; EvoCas9-1 was obtained after testing eleven designs, validated in the lab by an experimental biology subteam.
  • Still unknown: The page gives no success rates or error analysis, and an ethics and safety investigation addressed potential risks rather than efficacy.
  • AI role: Evo, a DNA-trained foundation model, designed the protein and RNA components of EvoCas9-1 and new IS200/IS605 transposons.

Evidence sources: https://arcinstitute.org/news/evo-science

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 737 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.